Projected Growth of the Global Branded Generics Market to Reach $588.37 Billion by 2029

Uncover key drivers, emerging technologies, and competitive movements shaping the branded generics market from 2025–2034 with trusted insights from The Business Research Company

What CAGR And Valuation Are Anticipated For The Branded Generics Market By The End Of 2029?

The branded generics market has seen significant expansion in recent years. This market is set to expand from $363.49 billion in 2024 to $393.5 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 8.3%. The historical increase can be ascribed to elements such as cost savings and affordability, patent expiries, market expansion and access, government initiatives and policies, and healthcare reforms.

The branded generics market size is anticipated to undergo swift expansion in the upcoming years. It is predicted to attain a value of $588.37 billion by 2029, achieving a compound annual growth rate (CAGR) of 10.6%. The expansion projected for the forecast period can be ascribed to factors such as the increasing demand for generic biologics, the prevalence of chronic diseases, the development of emerging markets, and an emphasis on biosimilars. Prominent trends identified for this period encompass strategic partnerships and collaborations, advancements in technology, a sustained focus on chronic diseases, market consolidation, and a patient-centric methodology.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7186&type=smp

Which Business Drivers Are Underpinning The Growth Of The Branded Generics Market?

The rising occurrence of chronic illnesses is set to propel the expansion of the branded generics market. These are persistent health conditions that frequently lack a definitive cure but can be managed and kept in check. Their rise is attributed to factors such as increased tobacco consumption, inadequate diet, lack of physical activity, excessive alcohol intake, among other causes. Globally, consumers are leaning towards branded generics for chronic disease treatment, drawn by their affordability compared to standard pharmaceutical options. As an example, the World Health Organization (WHO) 2022 Highlights, published in September 2022 by the Switzerland-based intergovernmental health organization, reported 41 million deaths annually worldwide, accounting for 74% of all fatalities, due to noncommunicable diseases (NCDs) or chronic diseases. Consequently, the growing prevalence of chronic diseases is anticipated to significantly elevate the demand for branded generics throughout the forecast timeframe.

What Are The Principal Segment Types In The Branded Generics Market?

The branded generics market covered in this report is segmented –

1) By Drug Class: Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptics, Other Drugs

2) By Route Of Administration: Topical, Oral, Parenteral, Other Routes Of Administration

3) By Application: Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics And Anti-inflammatory, Other Applications

Subsegments:

1) By Alkylating Agents: Nitrogen Mustards, Ethylene Imine Compounds

2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues

3) By Hormones: Corticosteroids, Thyroid Hormones

4) By Anti-Hypertensive: ACE Inhibitors, Beta Blockers, Calcium Channel Blockers

5) By Lipid Lowering Drugs: Statins, Fibrates

6) By Anti-Depressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

7) By Anti-Psychotics: Atypical Antipsychotics, Typical Antipsychotics

8) By Anti-Epileptics: Sodium Channel Blockers, GABAergic Drugs

9) By Other Drugs: Analgesics, Antibiotics, Antivirals

How Are Industry Trends Steering The Expansion Of The Branded Generics Market?

Strategic alliances represent a key development in the branded generics market. Companies operating within this sector are establishing collaborations with relevant entities to leverage shared resources and expand into new markets. For example, in September 2024, Biocon Ltd., an India-based pharmaceutical company, formed a partnership with Tabuk Pharmaceuticals. Biocon will take charge of the development and manufacturing of GLP-1 products, guaranteeing premium biopharmaceuticals specifically designed for diabetes treatment. Tabuk Pharmaceuticals will possess the marketing authorization rights, managing the registration, importation, and promotion of these products across the Middle East, particularly within Saudi Arabia. The agreement also includes provisions for future expansion into other GLP products beyond the initial offerings, allowing for a broader spectrum of diabetes treatments. This partnership aims to deliver distinctive health solutions that enhance patient well-being in Saudi Arabia and surrounding areas, aligning with both companies’ commitment to improving healthcare access. Tabuk Pharmaceuticals is a Saudi Arabia-based pharmaceutical company that markets both branded and generic pharmaceutical products.

Which Companies Are Contributing Significantly To The Branded Generics Market Growth?

Major companies operating in the branded generics market include Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Mylan N.V., Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Aspen Pharmacare Holdings Limited, Endo International plc, Towa Pharmaceutical Co. Ltd., Mankind Pharma, Glenmark Pharmaceuticals, Par Pharmaceuticals Inc., Unichem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Wockhardt, Intas Pharmaceuticals Ltd., Novartis International AG, Novo Nordisk A/S, Zydus Lifesciences Ltd.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report

Which Region Offers The Most Opportunity For Branded Generics Market Expansion?

North America was the largest region in the branded generics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=7186&type=smp

Browse Through More Reports Similar to the Global Branded Generics Market 2025, By The Business Research Company

Gastrointestinal Drug Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report

Nutritional Feed Additives Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nutritional-feed-additives-global-market-report

Pharmacies And Drug Stores Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pharmacies-and-drug-stores-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795